3-(Dipropylamino)-3,4-dihydro-2H-1-benzothiopyran-5-ol | 109140-21-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 硫铬烷
• 英文名称: 3-(Dipropylamino)-3,4-dihydro-2H-1-benzothiopyran-5-ol
• 英文别名: 3-(dipropylamino)-3,4-dihydro-2H-thiochromen-5-ol
• CAS: 109140-21-8
• 化学式: C₁₅H₂₃NOS
• 分子量: 265.4
• InChiKey: SFLCTKUTPODWQY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  18
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  48.8
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• Verwendung von Serotonin-Antagonisten bei der Behandlung von Apoplexia cerebri
  申请人：Troponwerke GmbH & Co. KG

  公开号：EP0360077A2

  公开（公告）日：1990-03-28

  Wirkstoffe, mit Serotonin-agonistischer Wirkung, die be­vorzugt an 5HT1A-Rezeptoren binden, werden zur Herstel­lung von Arzneimitteln zur Behandlung von Apoplexia cerebri verwendet.

  具有血清素拮抗作用的活性物质优先与 5HT1A 受体结合，可用于制造治疗脑瘫的药物。
• 3-Amino-dihydro-[1]-benzopyrane und Benzothiopyrane
  申请人：CIBA-GEIGY AG

  公开号：EP0222996B1

  公开（公告）日：1991-05-22
• NOVEL COMPOSITION FOR TREATING METABOLIC SYNDROME AND OTHER CONDITIONS
  申请人：Chen Chien-Hung

  公开号：US20120183600A1

  公开（公告）日：2012-07-19

  The invention relates to a composition that includes a first agent selected from the group consisting of an oxidative phosphorylation inhibitor, an ionophore, and an adenosine 5′-monophosphate-activated protein kinase (AMPK) activator; a second agent that possesses anti-inflammatory activity; and a third agent that possesses serotonin activity.
• PHARMACEUTICAL COMPOSITION COMPRISING AN AMPK ACTIVATOR AND A SEROTONERGIC AGENT AND METHODS OF USE THEREOF
  申请人：ALS MOUNTAIN LLC

  公开号：US20140350064A1

  公开（公告）日：2014-11-27

  The present invention is based on the unexpected discovery that a combination of certain known drugs exhibits synergistic effects in treating metabolic syndrome and various other diseases. In particular, the invention comprises a pharmaceutical composition comprising: (1) a therapeutically effective quantity of a first agent that is an AMPK activator; and (2) a therapeutically effective quantity of a second agent that possesses or maintains serotonin activity. A preferred composition comprises metformin hydrochloride and melatonin. The invention further comprises methods for the use of these compositions for the treatment of metabolic syndrome, hyperproliferative diseases including cancer, and other diseases and conditions.
• US4801605A
  申请人：——

  公开号：US4801605A

  公开（公告）日：1989-01-31